← All Ginkgo Bioworks Holdings, INC filings

Ginkgo Bioworks Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
DNA
Ginkgo Bioworks Holdings, INC
10-K: Ginkgo Bioworks Reports Reduced Losses Amid Revenue Decline and Strategic Restructuring
Ginkgo Bioworks Holdings, Inc. reported a significant reduction in its net loss for 2025, reaching $(312.8) million, despite a decrease in total revenue to $170.2 million, as the company continues its strategic restructuring and focuses on its core cell engineering platform.
NYSE
DNA
Ginkgo Bioworks Holdings, INC
10-K: Ginkgo Bioworks Reports FY24 Results, Focuses on Cell Engineering and Biosecurity Growth
Ginkgo Bioworks' FY24 results highlight a strategic shift towards cell engineering and biosecurity, amidst restructuring and operational changes.
NYSE
DNA
Ginkgo Bioworks Holdings, INC
10-K: Ginkgo Bioworks Details Capital Stock Structure and Shareholder Rights in SEC Filing
Ginkgo Bioworks outlines the specifics of its multi-class capital stock structure, including voting rights, economic rights, and conversion options, in a recent SEC filing.